To test the hypothesis that dopamine (DA) recep tors influence cerebral DOPA-decarboxylase (DDC) activity in vivo, we used HPLC to measure the kinetics of the cerebral uptake and metabolism of [3H]DOPA in carbidopa-treated rats, and in rats also treated acutely with a DA receptor antagonist
(flupenthixol, 2 mg/kg, intraperitoneally) or a DA receptor ago nist (apomorphine, 200 f, Lg/g, subcutaneously) . The unidirec tional blood-brain clearance of [3H]DOPA (K 1 DOPA , 0.030 mL g-' rnin�') increased by 50% after flupenthixol. The magni tudes of the relative DDC activity (k 3 DOPA ) in striatum (0.20 min-I), olfactory tubercle (0.11 min-I), and hypothalamus (0.15 min-{ ') of carbidopa-treated rats were doubled with flu penthixol, but cortical DDC activity was unaffected (0.02 min-I). Apomorphine reduced the magnitude of k 3 DOPA in It has been claimed recently that the activity of L-3,4dihydroxypenylalanine (DOPA) decarboxylase (DDC) in living striatum determines the fraction of DOPA that is trapped as dopamine (DA) and not cleared from brain by facilitated diffusion or metabolism (Gjedde et aI., 1993; Cumming et aI., 1995a; Opacka-Juffry and Brooks, 1995) . DOPA formed in brain is not committed solely to catecholamine synthesis (Cumming et aI., submitted) . By competing with other processes causing elimination of DOPA from brain, DDC activity may coregulate cerebral DA synthesis with tyrosine hydroxylase and may be rate limiting for the synthesis of DA in patients with Parkin son's disease. It has been noted that DDC from rat stria tum, its activity measured ex vivo, is activated after treat ment with DA receptor antagonists such as flupenthixol striatum by 20%. The rate constant for catabolism of eH]DA formed in brain (k/, monoamine oxidase [MAO] activity), which ranged from 0.025 min�l in striatum to 0.08 min-1 in hypothalamus of carbidopa-treated rats, globally increased 2-to 4-fold after flupenthixol, and decreased to 0.003 rnin�' in stria tum after apomorphine. These in vivo results confirm the claim that acute blockade of DA receptors with flupenthixol stimu lates the synthesis of [3H]DA from [3H]DOPA, and that this [3H]DA is subject to accelerated catabolism. Conversely, acti vation of the DA receptors with apomorphine inhibits DDC activity and DA catabolism. Key Words: DOPA-DOPA de carboxy lase-Re gula tion-Kineti c s-Antagon i s ts Agonists-Neuroleptics-Flupenthixol-Apomorphine. and is partially inactivated after treatment with apomor phine, a DA receptor agonist (Zhu et aI., 1992; Hadji constantinou et aI., 1993; Zhu et aI., 1994) . These results suggest that an antagonist selective for DA autorecep tors, by stimulating DDC activity, might increase the rate of DA synthesis from exogenous DOPA and so potenti ate the therapeutic action of DOPA in Parkinson's dis ease. Conversely, apomorphine would be expected to reduce the rate of DA synthesis from exogenous DOPA. However, the effects of drugs binding to dopamine au toreceptors on the uptake and metabolism of DOPA in brain of living rat are unknown.
We have formulated a compartmental model describ ing the uptake and cerebral metabolism of 6-esp]fluoro L-3,4-dihydroxyphenylalanine (PDOPA, Cumming et aI., 1994) and eH]DOPA (Cumming et aI., 1995a) based on the temporal changes in the concentrations of labelled metabolites measured by HPLC fractionate of arterial plasma and brain extracts after bolus tracer injection. This model includes the fractional rate constant, also known as the relative rate constant, for the activity in vivo of DDC with respect to radiolabelled DOPA (k3 D O PA , min-I) relative to the corresponding Michaelis constants (k3 D OPA = V m a )Km). The model also defines activity in vivo of monoamine oxidase (MAO) relative to the corresponding Michaelis constants of MAO for DA.
The reported effects of drugs such as flupenthixol and apomorphine on DDC activity measured ex vivo in stria tal homogenates may be complicated by postmortem ef fects. Specifically, DDC activity measured in homog enized tissue may have been altered by disruption of the normal compartmentalization and regulation of the en zyme that prevailed in living brain. Therefore, we wished to confirm in vivo the regulation by flupenthixol and apomorphine of DDC activity reported on the basis of ex vivo assays under saturating conditions. The present model of eHlDOPA metabolism in vivo also tests the effects of flupenthixol and apomorphine on the rate con stants for the decomposition of labelled DA formed in living brain (k/).
METHODS
The kinetic model for eH]DOP A metabolism ( Fig. I) is discussed in detail elsewhere (Cumming et aI., 1994; Cumming et a!., 1995 a,b) . Briefly, in the periphery CH]DOPA is me tabolized by catechol-O-methyltransferase at the rate estab lished by the rate constant ko DOPA , yielding O-methyl [3H]DOPA (OMe-CH]DOPA) which is cleared from circula tion at thJ rate described by the rate constant k_ I O M D (Cumming et aI., 1993) .
[3H]DOPA is reversibly transferred across the blood-brain barrier by the facilitated diffusion of large neutral amino acids described by the blood-brain clear ance (K I DOPA , mL g-I min-I) and the rate constant of brain [3HjDOPAC and its metabolite eHjHV A are eliminated from brain at rates deter mined by the rate constants k9a and k9b respectively. Male Wistar rats (225 to 275 g, Charles River, Quebec, Canada) were anesthetized with halothane (2%, Ayerst, Canada) and received heparinized catheters in a femoral artery and vein as described previously (Cumming et a!., 1994 (Cumming et a!., ,1995 (Cumming et a!., ,1997 . Rats received carbidopa (5 mg/kg, intra peritoneally, Merck Sharp and Dohme Kirkland, Quebec, Canada) to block the peripheral decarboxylation of eH]DOPA, and saline (intraperitoneally, n = 10), cis-flupenthixol (2 mgl kg, intraperitoneally, Research Biochemicals, Inc., [Natick, MA, U.S.A.] n = 12), or apomorphine (200 f.Lg/kg, subcuta neously, Sigma [St. Louis, MO, U.S.A.], n = 14), before im mobilization in a plaster body cast. After 45 minutes recovery from anesthesia, rats received 100 f.LCi [3H]DOPA (L-3,4-[ring-2,5,6-3H]dihydroxyphenylalanine, 80 Cilmmol ; New Eng land Nuclear, Wilmington, DE, U.S.A.) as an intravenous bolus in 500 f.LL saline. Arterial blood samples were collected at intervals. The radiochemical composition of portions of plasma extracted with an equal volume of perchloric acid (0.5 mollL) was determined by HPLC fractionation combined with scintil lation spectroscopy as described elsewhere (Cumming et aI., 1995 a,b) . At circulation times ranging from 2.5 to 90 minutes, rats were killed by decapitation. Brains were rapidly dissected on ice into striatum, olfactory tubercle, cortex, hippocampus, and hypothalamus. Brain extracts, prepared by sonication in 10 volumes of 0.1 mollL perchloric acid, were fractionated by HPLC.
The concentrations of [3H]DOPA and its peripheral metabo lite O-methyl-[3H]DOPA in plasma, as functions of circulation time, were calculated from HPLC fractionation results. For experiments in which eH]DOPA circulation lasted more than 10 minutes, the rate constants describing peripheral metabolism of [3H]DOPA were calculated as described previously (Cum ming et aI, 1993 (Cum ming et aI, ,1994 (Cum ming et aI, ,1995 . For a popUlation of rats, the normalized arterial integrals (8, min-I, Gjedde, 1981 , 1982 , Patlak et aI., 1983 for [3H]DOPA,
were plotted as a function of the tracer circulation time. The linear regression slope of this relationship «(Y) was used to generate a single common curve for the arterial tracer concen tration (Ca DOPA , DPM/f.LL) using the following empirical rela tionship, a power function (Cumming et aI, submitted) ;
where A and To are arbitrary coefficients (1000 DPM/f.LL and I minute), T is the tracer circulation time (minutes), and (Y is the linear regression slope defined above. The ratios of the integral of the common arterial curve and the integrated arterial r3H]DOP A concentrations measured for each rat were used as linear scaling factors. For each rat, concentrations of radiotrac ers measured in plasma and brain were all corrected to the common arterial curve by an individual's scaling factor. Using Matlab software for nonlinear regression (Mathworks, Natick, MA, U.S.A.) we fitted the model arterial curve and the measured brain eH]DOPA concentrations (Mt DOPA , DPMI mg) to a one-compartment model defined only by the unidi rectional blood-brain clearance of [3H]DOPA (K I DOPA ) and the rate constant for the net clearance of eH]DOP A from brain (kc1 DOPA , min-I ), comprising the sum of the rate constants of clearance of r3H]DOP A from brain by transport from brain to blood (k2 DOPA ) , decarboxylation in brain (k 3 DOPA ) and 0methylation in situ (ks DOPA );
The kinetic constants so calculated were used to generate time-functions of the concentrations of eH]DOPA in each brain region. The time-activity curves of the calculated con centrations of eH]DOP A in brain, and the scaled concentra tions of eH]DA measured in brain (M t DA ), were used together to calculate k 3 DOPA and k/ by the linear regression described previously (Cumming et a!., 1994) ,
where k 3 D is the line's ordinate-intercept and -k/ its slope.
Each parameter is reported with its regression estimate and the 95% confidence intervals. Statistical significance of drug ef fects on peripheral pharmacokinetics was calculated by the Stu dent's t-test for repeated measures ; significance of nonlinear regression estimates was tested by the z-test.
RESULTS
In carbid(()pa-treated rats, the mean (± SEM) apparent rate constants for the O-methylation of eH]DOPA in circulation was 0.014 ± 0.002 min-I , while the mean rate constant for the elimination of OMe-[ 3 H]DOPA from circulation was 0.006 ± 0.003 min-1 (Table 1) . The elimination rate constant increased to 0.022 ± 0.007 min-1 in flupenthixol-treated rats (P < 0.00 1). The rela tionship between tracer circulation time and the normal ized arterial integrals in a population of carbidopa treated rats is illustrated in Fig. 2A . The linear regression slopes of the ratios (0: in Equation 1, ± 95 % confidence limits) for [ 3 H]DOPA were 2.1 ± 0. 1 in carbidopa-treated rats, 2.3 ± 0. 1 in flupenthixol-treated rats, and 2.2 ± 0. 1 in apomorphine-treated rats. An arterial curve common to all rats was calculated from Equation 1 with the mean coefficient of 2.2. This common arterial curve was plot- Saline (6) Flupenthixol (8) Apomorphine (7) 0.014 ± 0.002 0.016 ± 0.001 0.016 ± 0.002 0.006 ± 0.003 0.022 ± 0.007* 0.010 ± O.003t
Each estimate is the mean ± SEM of estimates obtained in (n) ani mals in which tracer circulation lasted longer than 15 minutes. Rats were treated with carbidopa (5 mg/kg, intraperitoneally) and saline (n = 6), flupenthixol (2 mg/kg, intraperitoneally, n = 8) or apomorphine (200 J..l-g/kg, subcutaneously, n = 7). Significance of difference from saline group: *p < 0.001, tnot significant. ted along with the eH]DOP A concentrations measured in an individual rat after scaling to this common input function (Fig. 2B) .
The measured and calculated eHlDOP A concentra tions in cerebral cortex and in striatum of carbidopa treated rats, and rats also receiving flupenthixol or apo morphine, are illustrated in Fig. 3 . The mean (± SEM) unidirectional blood-brain clearances of eH]DOPA (K] D O PA ) were 0.030 ± 0.004 mL g-l min-] in five brain regions of carbidopa-treated control rats, 0.047 ± 0.009 mL g-l min-1 in five regions of rats also receiving flu penthixol (P < 0.001 in each of five regions), and 0.027 Each point is the mean of two or three determinations, all scaled to a single common arterial curve for [3H]DOPA. The smooth curves are the nonlinear regressions of the fitted to the data for a one-compartment model described by the unidirectional blood brain clearance ( K , DOPA , mL g-' min-1) and the fractional rate constant for the net clearance of [3H]DOPA from brain (k"I DOPA , min-1) using the common arterial input. mL g-l min-1 in two regions of apomorphine-treated rats ( The unidirectional blood-brain clearances fo r t'HjDOPA (K/JOPA, mL g-l min-I )
Saline
Flupenthixol Apomorphine Striatum 0.019 ± 0.001 0'()26 ± 0.00 I * 0.029 ± 0.002* Olfactory tubercle 0.033 ± 0.001 0.047 ± 0.00 I * NA Cortex 0.039 ± 0.00 I 0.068 ± 0.002* 0.025 ± 0.00 I * Hippocampus 0.036 ± 0.00 I 0.058 ± 0.002* NA Hypothalamus 0.025 ± 0.001 0.034 ± 0.001 * NA Clearances estimated in five brain regions of (n) rats treated with carbidopa (5 mg/kg, intraperitoneally) and saline (n = 10), t1upen thixol (2 mg/kg, n = 12), or apomorphine (200 [Lg/kg, subcutaneously. n = 14) 45 minutes before tracer administration (100 [LCi, intrave nously). Kinetic parameters were calculated from the concentrations of r 3 H]DOPA in the common arterial curve and the scaled [ , H]DOPA concentrations measured in brain as a function of circulation time. A two-compartment kinetic model defined by the unidirectional blood brain clearance (K1 DOPA ) and the rate constant for the elimination of [ , H]DOPA from brain (kcl DOPA ) was fitted to these data by nonlinear regression. Each estimate is reported ±95% coincidence intervals. NA, not analyzed. Significance of difference from estimate in saline-treated group: * P < 0.001. treated with carbidopa and saline, flupenthixol, or apo morphine (Fig. 4) . In the saline-treated group, the mag nitude of k 3 D OP A was 0.02 min-I in cortex, 0. 15 min-1 in hypothalamus, 0. 11 min-I in olfactory tubercle and 0.20 min-I in striatum (Table 3) . Flupenthixol-treatment pro duced twofold increases in the magnitude of k 3 D OP A in striatum, olfactory tubercle and hypothalamus (P < 0.001), but was without effect in cortex. In apomorphine treated rats, the magnitude of the estimate of k 3 D OP A decreased to 0. 16 min-1 in striatum (P < 0.05), but in creased to 0.05 min-1 in cortex (P < 0.001).
The estimates of the rate constants of the catabolism of eH]DA formed within brain from eH]DOPA in car bidopa-treated rats (k/) ranged from 0.025 min-1 in striatum to 0.08 min-I in hypothalamus (Table 4 ). Flu penthixol-treatment increased the magnitude of the esti mate of k/ to 0. 1 min-1 in striatum and olfactory tu bercle, 0.2 min-I in cortex, and 0.3 min-1 in hypothala mus (P < 0.001), but was without effect in hippocampus. Apomorphine decreased the estimate of k/ to 0.003 min-1 in striatum (P < 0.001), but was without signifi cant effect in cortex.
DISCUSSION
The estimates of the magnitude of the fractional rate constants f of formation and elimination of OMe eH]DOPA in the circulation in carbidopa-treated rats (Table 1) (Cumming et aI., 1993) , possibly also related to renal clearance. It is the activation of dopamine D1-like sites that increases urine flow (Eisner et aI., 1994) ; the mechanism by which Rate constants estimated in five brain regions of (n) rats after ad ministration of [ ' HlDOPA (100 [LCi, intravenously) . Rats were treated with carbidopa (5 mg/kg, intraperitoneally) and saline (n = 10), t1u penthixol (2 mg/kg, intraperitoneally, n = 12), or apomorphine ( The relationship between the tracer circulation time and the normalized arterial integral for eH]DOP A is highly linear within a population of rats ( Fig. 2A) . The slope of this relationship (a) for eH]DOPA is identical to earlier estimate for eH]tyrosine (Cumming et aI., sub mitted), suggesting that distribution of the two labelled amino acids in circulation is very similar. Linear scaling of eH]DOP A concentrations measured in an individual rat during 120 minutes of tracer circulation results in very close agreement with the normalized arterial curve (Fig. 2B) . Thus, the modelling of the arterial eH]DOPA curves from a population of rats with a common power function (Equation 1) provides a satisfactory means of pooling data for compartmental analysis of dynamic time-activity curves.
The magnitudes of the unidirectional blood-brain clearances of eH]DOPA (Kl D OP A ) in carbidopa-treated rats were in the range of earlier estimates (Cumming et aI., 1995 a,b) . Apomorphine was without consistent ef fect on unidirectional blood-brain clearance, but flupen thixol globally increased the estimate of Kl D OP A by 50% (Table 2 ). Unidirectional clearance of eH]DOP A is po tentially sensitive to plasma concentrations of amino ac ids and cerebral blood flow, both of which could, in principle, be drug sensitive. However, the magnitudes of Kj D OP A in the flupenthixol group were still within the range of control values obtained previously (Cumming et aI., 1995 a,b) . Acutely, neuroleptics stimulate catecholamine synthe sis in rat striatum by activation of tyrosine hydroxylase (Zivkovic et aI., 1974 , Lazar et aI., 1982 . Chronically, neuroleptics increase the ex pression of mRNA for DDC in nigrostriatal neurons (Buckland et aI., 1992) . In the present study, acute treat ment with flupenthixol substantially activated DDC in striatum, olfactory tubercle, and hypothalamus (Table 4) , a finding consistent with the results of DDC assays ex vivo after acute treatment with flupenthixol and other antagonists of DA (Dl and D2) receptors (Zhu et aI., 1992; Hadjiconstantinou et aI., 1993 , Zhu et aI., 1994 . However, .the binding sites in rat striatum that regulate DA synthesis are now understood to be, in part, D3 re ceptors (Meller et aI., 1993) . In the present study, the receptors and pathways mediating DDC activation in vivo cannot be identified with certainty because flupen thixol is a nearly equipotent antagonist of Dl (Gingrich et aI., 1992) , D2, and D3 receptors (Freedman et aI., 1994) in vitro.
The dose of apomorphine administered in the present study is intermediate between the autoreceptor dose, and the higher psychomotor-stimulant dose activating post synaptic Dl and D2 receptors (Widzowski and Cory Slechta, 1993) . Partial inactivation of DDC by apomor phine in synaptosomes from rat striatum could not be overcome by flupenthixol (Zhu et aI., 1994) , indicating a complex pharmacology for the regulation of DDC in vivo. In th tt present study, the relative activity of DDC in intact striatum was reduced by 20% by acute apomor phine. Nonetheless, continuous infusion of apomorphine has been reported to reduce substantially the required dose of DOPA in a group of patients with Parkinson's disease (Gancher et aI., 1995) . The content of the DA metabolites in cerebrospinal fluid of non-parkinsonian subjects was substantially reduced for several hours after acute apomorphine administration (Przedborski et aI., 1995) . In the present study, apomorphine nearly arrested the catabolism of eH]DA formed in rat striatum, con sistent with the substantial decreases in DOPAC and HV A content of rat striatum observed 60 minutes after apomorphine (Westerink and Spaan, 1982) . Presumably the clinical antiparkinsonian postsynaptic effects of apomor phine can predominate over effects on DDC activity and DA metabolism mediated by presynaptic autoreceptors.
In an earlier study, we observed that acute inhibition of MAO with pargyline resulted in 50% reductions of the magnitude of k3 DOPA in striatum and olfactory tubercle, but no change in hypothalamus or cerebral cortex (Cum ming et al., 1995a) . To explain this phenomenon, we proposed that pargyline treatment, by blocking DA ca tabolism, increased the occupation of autoreceptors on nigrostriatal terminals by DA, causing in turn a partial inactivation of DDC. Conceivably the balance of factors regulating DDC activity in living hypothalamus favors the inactivated state of DDC such that acute pargyline was without effect on k3 DOPA . However, decarboxylation of eH]DOP A in vivo may substantially occur within serotonin terminals in some brain regions (Cumming et aI., 1995a , Cumming et aI., 1997 . Furthermore, haloper idol-treatment failed to activate tyrosine hydroxylase ac tivity in hypothalamus (Cumming et al., 1997a) . There fore, it is unclear why flupenthixol should activate DDC in hypothalamus in the present study. Flupenthixol was without effect on k3 DOPA in cortex, whereas apomor phine decreased the magnitUde of k3 DOPA in that tissue.
However, estimates of kinetic rate constants in cortex and hippocampus are based on measured [ 3 H]DA con centrations that are generally so low as to be unreliable.
The relative activities of MAO with respect to eH]DA formed in situ (k/, Table 4 ) are close to the magnitudes of the rate constants reported in an earlier study (Cum ming et aI., 1995a) . As before, the highest estimate of this rate constant was in hypothalamus, although the present result is 50% lower than the earlier estimate, possibly reflecting more rapid processing of postmortem specimens in the present study. Rate constants of inter mediate magnitude for MAO activity, relative to eH]DA, were again found in cortex, although with large relative errors caused by the low magnitude of k3 D in that tissue. In the present study, we again find evidence for a dorsal-ventral gradient in the magnitude of k/ within the basal ganglia consistent with the different DOP AC turn over rates observed in rat dorsal striatum and olfactory tubercle (Westerink and Kikkert, 1986 ). In the present study, acute treatment with flupenthixol greatly acceler ated the rate constant of catabolism of eH]DA formed from eH]DOP A within brain, consistent with the effect of acute neuroleptics on DOPAC and HVA measured in extracts of rat striatum (Westerink and Spaan, 1982) .
The schema in Fig. 1 suggests that DA catabolism in vivo proceeds in proportion to the distribution of DA between cytosolic and vesicular compartments, because only cytosolic DA is accessible to catabolic enzymes. Were DA synthesis acutely stimulated, the vesicular stor age sites may plausibly become saturated, in which event newly synthesized DA would remain in the cytosol where it would be rapidly decomposed by MAO. Con sistent with this model, acute treatment with haloperidol does not alter the total DA content of intact rat striatum, although DA metabolite concentrations are greatly in creased (Westerink and Spaan, 1982) . Thus, the present model suggests that stimulation of the pathway for DA synthesis is futile with respect to steady-state DA levels if the vesicular DA compartment is nearly saturated. The present finding that flupenthixol stimulates the formation of DA from exogenous L-DOPA in rat brain suggests that a selective autoreceptor antagonists might potentiate the antiparkinsonian action of DOPA. However, it is dif ficult to predict the clinical consequences of stimulated DA synthesis in brain of patients with Parkinson's dis ease, in whom the vesicular storage of DA may also be compromised.
In conclusion, the present in vivo tracer kinetic study provides further evidence for a regulation of DDC activ ity in brain of living rat. Chronic DOPA administration decreases the synthesis of DA and the activity of DDC in rat striatum measured ex vivo (Melamed et aI., 1983; Takashima et aI., 1987; Murata et aI., 1993) . In a recent PET study in anesthetized nonhuman primates, acute DOPA treatment increased the magnitude of k 3 DOPA in striatum by about 20% (Tedroff et aI., 1997) . We have elsewhere argued that the presence of competing path ways suggests that DOPA entering brain (Gjedde et aI., 1993) or formed within brain (Cumming' et aI., in press) is not wholly committed to catecholamine synthesis. The activity of DDC in vivo determines the fraction of DOPA within brain that is transformed into DA. From earlier estimates of the rate constant for elimination of [ 3 H]DOPA from rat brain (Cumming et aI., 1995a) , we can calculate that acute flupenthixol increased this frac tion from 60% to 80%, thus contributing to the regulation of DA synthesis. Together with earlier findings, the pres ent results suggest that DDC activity and expression may be regulated in proportion to the occupancy of DA au toreceptors, and that DDC activity in striatum of living rat is poised at an intermediate state of activation. The precise pharmacology of this regulation is at present uncertain. Sludies with centrally acting drugs more se lective for DA autoreceptors than flupenthixo1 or apo morphine may be informative about the presynaptic mechanisms regulating DDC activity in vivo. A clear understanding of these mechanisms could result in im proved pharmacotherapy for Parkinson's disease, espe cially if DDC activity were stimulated with DA antago nists acting only presynaptically.
